Who Owns Lovenox?

Lovenox's development originated from research into low-molecular-weight heparins (LMWHs) as improved alternatives to unfractionated heparin (UFH), which had been the standard anticoagulant since the 1930s. Unfractionated heparin had significant clinical limitations: unpredictable pharmacokinetics requiring laboratory monitoring, intravenous administration or frequent subcutaneous injections, and variable patient response.

Enoxaparin was developed by depolymerizing unfractionated heparin to produce shorter oligosaccharide chains with a mean molecular weight of approximately 4,500 daltons, compared to approximately 15,000 daltons for UFH. This chemical modification produced more predictable pharmacokinetics and a higher ratio of anti-Factor Xa to anti-Factor IIa activity, resulting in more selective anticoagulation with a lower bleeding risk profile.

Rhone-Poulenc Rorer first marketed Lovenox in Europe in 1987. The U.S. Food and Drug Administration approved Lovenox on March 27, 1993, for prevention of deep vein thrombosis (DVT) in patients undergoing hip replacement surgery. The FDA approval was based on clinical trial data showing that enoxaparin reduced the risk of postoperative blood clots compared to standard heparin therapy. At launch, the average wholesale price for a seven-day course of treatment was approximately $161.

Subsequent FDA approvals expanded Lovenox's indications throughout the 1990s and 2000s. The drug received approval for DVT prevention in knee replacement surgery, abdominal surgery, and medical patients with severely restricted mobility. Treatment indications were added for acute DVT with or without pulmonary embolism (PE), prophylaxis of ischemic complications in unstable angina and non-ST-elevation myocardial infarction (NSTEMI), and treatment of acute ST-elevation myocardial infarction (STEMI) in combination with thrombolytic therapy.

Lovenox became the dominant anticoagulant in hospital settings and the first widely used injectable anticoagulant suitable for outpatient DVT treatment. Its predictable pharmacokinetics allowed fixed weight-based subcutaneous dosing without routine laboratory monitoring, enabling patients to self-administer at home rather than requiring hospitalization for intravenous heparin infusion. Peak annual global revenues reached approximately $4 billion in the mid-2000s, making Lovenox one of Sanofi's most commercially successful products.

The FDA approved the first generic enoxaparin sodium, manufactured by Sandoz (the generics division of Novartis), on July 23, 2010. The approval was scientifically complex because enoxaparin is a biological mixture of oligosaccharides rather than a conventional small-molecule drug, making bioequivalence demonstration more challenging. Sanofi filed a lawsuit against the FDA seeking to block the generic approval, arguing that generic enoxaparin could not be proven bioequivalent to Lovenox using standard pharmacokinetic measures. The lawsuit was unsuccessful.

Generic enoxaparin rapidly eroded Lovenox's market share and revenue. By 2026, Sanofi reported Lovenox sales of €180 million in Q2 2026, down 15.8% year-over-year due to continued biosimilar pressure. The brand has shifted from a blockbuster product to a declining legacy brand within Sanofi's General Medicines portfolio.

The anticoagulant market has also been transformed by direct oral anticoagulants (DOACs) including rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and dabigatran (Pradaxa). These oral drugs offer convenient administration without injections or routine monitoring, further reducing demand for injectable LMWH products like Lovenox in outpatient settings.